Drug Trial Radar · NCT06558513
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Aug 3, 2021
Primary completion
Aug 30, 2025
Study completion Aug 30, 2025
Sponsor
- Lead sponsor
- Evopoint Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
Conditions
- Advanced Tumor
- Lymphoma
Interventions
XNW5004 tabletsDrug
XNW5004 an EZH2 inhibitor, BID, administered in continuous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (AEs)[Safety and Tolerability]Time frame: through study completion, an average of about 10 months
- Recommended phase 2 dose (RP2D)Time frame: 28 days since the date of first dose in phase 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.